Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Recruiting 139Active not recruiting 51Not yet recruiting 32Completed 31Terminated 13Withdrawn 4Suspended 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Neoplasms 12Prostatic Neoplasms 8Recurrence 4Lung Neoplasms 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Lymphoma, B-Cell 3Lymphoma 3Colorectal Neoplasms 3Cancer Pain 3Uterine Cervical Neoplasms 2Urologic Neoplasms 2Triple Negative Breast Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pain 2Ovarian Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Head and Neck Neoplasms 2Glioblastoma 2Cholangiocarcinoma 2

Interventions

fludarabine 2pelcitoclax 1Vincristine 1Rituximab 1Quality Assurance, Health Care 1Prednisone 1Lisaftoclax 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Doxorubicin 1Cytarabine 1Cyclophosphamide 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × 90 days × Clear all
NCT07428486 2026-05-07

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07453446 2026-05-06

Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Phase 1 Withdrawn
Lymphoid

Lymphoma, Recurrence

NCT07484282 2026-04-03

Quality of Care for Adolescent and Young Adult (AYA) Patients Living With Serious or Advanced Cancer

National Institutes of Health Clinical Center (CC)

Withdrawn

Death, Neoplasms, Recurrence

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3 Withdrawn
Lymphoid

Lymphoma, Follicular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡